Factors associated with response to lamivudine: Retrospective study in a tertiary care clinic serving patients with chronic hepatitis B

Journal of Gastroenterology and Hepatology (Australia)

Volumn 20, Issue 3, 2005, Pages 433-440

  Hann, Hie Won L ^a,e   Funk, Michele L Jonsson ^b   Rosenberg, Daniel M ^c   Davis, Randy ^d  

^a THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c GLAXOSMITHKLINE   (Singapore)

^d GLAXOSMITHKLINE   (United States)

^e THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Chronic hepatitis B; Lamivudine; Treatment

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; VIRUS DNA;

ADOLESCENT; ADULT; AGED; ARTICLE; CHRONIC HEPATITIS; DISEASE ACTIVITY; DISEASE COURSE; FEMALE; HAZARD ASSESSMENT; HEPATITIS B; HOSPITAL; HUMAN; HUMAN CELL; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL; THROMBOCYTE COUNT; TREATMENT OUTCOME;

EID: 16344381152     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2005.03577.x     Document Type: Article

References (27)

1. Beasley RP. Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer 1988; 61: 1942-56.
2. Blumberg BS, London WT. Hepatitis B virus: Pathogenesis and prevention of primary cancer of the liver. Cancer 1982; 50: 2657-65.
3. World Health Organization. Hepatitis B Factsheet No. 204. [Cited 14 Dec 2004], Available from URL: http://www.who.int/mediacentre/factsheets/fs204/en.
4. Hann HW, Kim CY, London WT, Whitford P, Blumberg BS. Hepatitis B virus and primary hepatocellular carcinoma: family studies in Korea. Int. J. Cancer 1982; 30: 47-51.
5. Larouze B, Saimot G, Lustbader ED, London WT, Werner BG, Payer M. Host responses to hepatitis-B infection in patients with primary hepatic carcinoma and their families. A case/control study in Senegal, West Africa. Lancet 1976; 2: 534-8.
6. McMahon BJ. Hepatocellular carcinoma and viral hepatitis. In: Willson RA, ed. Viral Hepatitis: Diagnosis, Treatment, Prevention. New York: Dekker, 1997; 315-30.
7. Hoofnagle JH, Peters M, Mullen KD et al. Randomized, controlled trial of recombinant human alpha-interferon in patients with chronic hepatitis B. Gastroenterology 1988; 95: 1318-25.
8. Perrillo RP, Schiff ER, Davis GL et al. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group. N. Engl. J. Med. 1990; 323: 295-301.
9. Brook MG, Karayiannis P, Thomas HC. Which patients with chronic hepatitis B infection will respond to α-interferon therapy? A statistical analysis of predictive factors. Hepatology 1989; 10: 761-3.
10. Lok AS, Lai CL, Wu PC, Lau JY, Leung EK, Wong LS. Treatment of chronic hepatitis B with interferon: experience in Asian patients. Semin. Liver Dis. 1989; 9: 249-53.
11. Perrillo R, Tamburro C, Regenstein F et al. Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus. Gastroenterology 1995; 109: 908-16.
12. Hoofnagle JH, Di Bisceglie AM, Waggoner JG, Park Y. Interferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B. Gastroenterology 1993; 104: 1116-21.
13. Dienstag JL, Schiff ER, Wright TL et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N. Engl. J. Med. 1999; 341: 1256-63.
14. Lai CL, Chien RN, Leung NW et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N. Engl. J. Med. 1998; 339: 61-8.
15. Schalm SW, Heathcote J, Cianciara J et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut 2000; 46: 562-8.
16. Liaw YF, Leung NW, Chang TT et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterol 2000; 119: 172-80.
17. Leung NW, Lai CL, Chang TT et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001; 33: 1527-32.
18. Chang TT, Lai CL, Liaw YF et al. Incremental increase in HBeAg seroconversion and continued ALT normalization in Asian chronic HBV (CHB) patients treated with lamivudine for four years (abstract). Antivir. Ther. 2000; 5 (Suppl. 1): 44.
19. Dienstag JL, Goldin RD, Heathcote EJ et al. Histological outcome during long-term lamivudine therapy. Gastroenterology 2003; 124: 105-17.
20. Perrillo RP, Schalm SW, Schiff ER, Brown NA, Woessner MA, Sullivan M. Predictors of HBsAg seroconversion in chronic hepatitis B patients treated with lamivudine (abstract). Hepatology 1999; 30: 317A.
21. Guan R, Lai CL, Liaw YF, Lim SG, Lee CM. Efficacy and safety of 5 years lamivudine treatment of Chinese patients with chronic hepatitis B (abstract). J. Gastroenterol. Hepatol. 2001; 16 (Suppl.): A60.
22. Ellis G, Goldberg DM, Spooner RJ, Ward AM. Serum enzyme tests in diseases of the liver and biliary tree. Am. J. Clin. Pathol. 1978; 70: 248-58.
23. Hann HW, Fontana RJ, Wright TL et al. A United States compassionate use study of lamivudine treatment in non-transplantation candidates with decompensated hepatitis B virus-related cirrhosis. Liver Transpl. 2003; 9: 49-56.
24. Kim CY, Bae SK, Kann HW, London WT, Blumberg BS. Prevalence of HBeAg and anti-HBe in chronic active hepatitis, cirrhosis and primary hepatocellular carcinoma in Korea. Hepatology 1985; 5: 54-6.
25. Ito K, Mitchell DG, Hann HW et al. Progressive viral-induced cirrhosis: serial MR imaging findings and clinical correlation. Radiology 1998; 207: 729-35.
26. Simpson KJ, Findlayson NDC. Clinical evaluation of liver disease. Bailliere's Clinical Gastroenterology 1995; 9: 639-59.
27. Lee S, Han S, Cho S et al. Distribution of HBV genotypes in patients with chronic HBV infection in Korea. Korean J. Hepatol. 2001; 7: 373-80.